首页> 外文OA文献 >Long‐term overall‐ and progression‐free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non‐Hodgkin lymphoma

【2h】

Long‐term overall‐ and progression‐free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non‐Hodgkin lymphoma

机译：五稳素，环磷酰胺和利妥昔单抗治疗后的长期总体和无进展存活，用于惰性非霍奇金淋巴瘤

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Tamer Khashab; Fredrick Hagemeister; Jorge E. Romaguera; Michelle A. Fanale; Barbara Pro; Peter McLaughlin; M. Alma Rodriguez; Sattva S. Neelapu; Luis Fayad; Anas Younes; Lei Feng; Francisco Vega; Larry W. Kwak; Felipe Samaniego;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma [J] . Khashab Tamer, Hagemeister Fredrick, Romaguera Jorge E., British Journal of Haematology . 2019,第4期

机译：五稳素，环磷酰胺和利妥昔单抗治疗后的长期总体和无进展存活，用于惰性非霍奇金淋巴瘤
2. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. [J] . Hochster H, Weller E, Gascoyne RD, Journal of Clinical Oncology . 2009,第10期

机译：环磷酰胺，长春新碱和泼尼松治疗后维持利妥昔单抗可延长晚期惰性淋巴瘤的无进展生存期：III期ECOG1496随机研究的结果。
3. Prolonged progression-free survival and preserved quality of life in the Canadian prospective study of tositumomab and iodine(131)-tositumomab for previously treated, rituximab-exposed, indolent non-Hodgkin lymphoma [J] . Olney Harold J., Freeman Marni A., Stewart Douglas A., Leukemia and lymphoma . 2014,第12期

机译：在加拿大tositumomab和iodine（131）-tositumomab的加拿大前瞻性研究中，先前治疗过的，利妥昔单抗暴露，惰性的非霍奇金淋巴瘤的无进展生存期延长和生命质量得以保留
4. Autotransplant Approach with Rituximab in High Grade Primary Refractory or Progressive Non Hodgkin's Lymphomas (NHL). 2nd Report [C] . D. Vallisa, A. Lazzaro, R. Berte, European Haematology Association . 2002

机译：用Rituximab在高级初级耐火或渐进非霍奇金淋巴瘤（NHL）中的rituximab的自同毒性方法。第二次报告
5. Systems pharmacology modeling of rituximab and doxorubicin in non-Hodgkin's lymphoma. [D] . Zhao, Xiaochen. 2016

机译：非霍奇金淋巴瘤中利妥昔单抗和阿霉素的系统药理模型。
6. Maintenance Rituximab After Cyclophosphamide Vincristine and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study [O] . Howard Hochster, Edie Weller, Randy D. Gascoyne, -1

机译：环磷酰胺长春新碱和泼尼松治疗后维持利妥昔单抗可延长晚期惰性淋巴瘤的无进展生存期：III期ECOG1496随机研究结果
7. Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study [O] . Hochster, Howard, Weller, Edie, Gascoyne, Randy D., 2009

机译：环磷酰胺，长春新碱和泼尼松治疗后维持利妥昔单抗可延长晚期惰性淋巴瘤的无进展生存期：III期ECOG1496随机研究结果

Long‐term overall‐ and progression‐free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non‐Hodgkin lymphoma

著录项

相似文献

相关主题

期刊订阅